MarketInOut Stock Screener Log In | Sign Up
 

Cadrenal Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Cadrenal Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2.97 mln
Float3.10 mln
Earnings Date11/05/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

90 / 100
Top performer

ROE

-369
Deeply negative

ROA

-253
Deeply negative

Business Description

Cadrenal Therapeutics is a Florida-based pharmaceutical company working to bring a new blood-thinning medication called Tecarfarin to patients with serious heart and circulatory conditions. Unlike many existing treatments, Tecarfarin is taken by mouth and can be reversed if needed, making it a promising option for people living with mechanical heart pumps, advanced kidney disease, or conditions that cause dangerous blood clotting. The company has partnered with Abbott Global Enterprises to study how well Tecarfarin works in patients who rely on mechanical heart pump devices.

Key Fundamentals

EPS-4.91
ROE-369
ROIC-1,531
ROA-253
EBITDA, mln-11.54
EV / EBITDA-0.07
EV / EBIT-0.07

Quote Details

Last 0.96
Change -0.01 (-1.03%)
Open 0.965
Volume 38,135
Turnover 36,610
Average Volume 205,299

Financial Ratios

Leverage Ratio1.37
Current Ratio3.67
Price / Book0.80
Price / Tangible Book0.80

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio0.09
Short % of Float3.31

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -11.93% 7 / 100   
1 Month -20% 18 / 100   
2 Months -54.07% 7 / 100   
6 Months -82.55% 4 / 100   
1 Year -92.31% 4 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog